Merrill Lynch Reports That They Have Downgraded GlaxoSmithKline (NYSE:GSK) Shares

Marco Green
January 14, 2018

Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company's stock worth $175,000 after acquiring an additional 788 shares in the last quarter. The company has market cap of $85.40 billion. The shares were sold at an average price of GBX 1,310 ($17.52), for a total transaction of £262,000 ($350,314.21).

GlaxoSmithKline plc (GSK) is a healthcare company. It has underperformed by 16.70% the S&P500.

Gruss & Co Inc increased its stake in Biogen Inc (BIIB) by 125% based on its latest 2017Q3 regulatory filing with the SEC. The shares were bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The hedge funds in our database now own: 3.38 million shares, down from 4.53 million shares in 2017Q2.

The company has a market cap of $66,770.00 and a PE ratio of 2,805.83. About 265,995 shares traded. Rand Logistics, Inc. (RLOG) has declined 27.05% since January 10, 2017 and is downtrending. It has underperformed by 11.76% the S&P500.

Investors sentiment increased to 0.74 in 2017 Q3. It's down -0.09, from 0.54 in 2017Q2. It increased, as 59 investors sold BIIB shares while 283 reduced holdings. 31 funds opened positions while 77 raised stakes. Coldstream Capital Management Inc. purchased a new stake in shares of GlaxoSmithKline in the third quarter worth approximately $237,000. Bnp Paribas Arbitrage Sa has 0% invested in Voya Financial, Inc. (NASDAQ:BIIB). Putnam Fl Investment Mgmt Company holds 0.11% in Biogen Inc. There has been an observed change of 0.00% in the ownership of the shares in the past six months. Accern also gave news headlines about the pharmaceutical company an impact score of 46.6510607046145 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Spruce House Investment Management Llc holds 33.93% of its portfolio in XPO Logistics, Inc. for 7.75 million shares. Highland Mgmt LP has invested 0.26% in Cavium, Inc. 869 were reported by Guardian L P. 15,566 were accumulated by Cullen Frost Bankers.

Among 24 analysts covering Cavium Networks Inc. The stock of GlaxoSmithKline plc (NYSE:GSK) earned "Buy" rating by Bryan Garnier & Cie on Wednesday, January 27. Therefore 81% are positive. American Capital Senior had 5 analyst reports since November 3, 2015 according to SRatingsIntel. Oppenheimer initiated Biogen Inc.

The company's stock is now moving with a -ve distance from the 200 day SMA of approximately -9.08%, and has a solid year to date (YTD) performance of 2.62% which means that the stock is constantly adding to its value from the previous fiscal year end price. The stock of Biogen Inc. SignalPoint Asset Management LLC now owns 6,578 shares of the pharmaceutical company's stock worth $285,000 after buying an additional 1,025 shares during the period. The firm has "Buy" rating given on Monday, December 7 by Argus Research. The firm has "Buy" rating by Jefferies given on Thursday, July 14. As per Tuesday, October 25, the company rating was maintained by JP Morgan. (NASDAQ:BIIB) earned "Strong Buy" rating by Raymond James on Thursday, December 29. The firm earned "Buy" rating on Tuesday, August 11 by H.C. Wainwright. The firm has "Buy" rating by Sandler O'Neill given on Monday, November 13. Citigroup maintained it with "Neutral" rating and $10 target in Wednesday, August 10 report.

GlaxoSmithKline plc (NYSE:GSK) reported its EPS in the last quarter as $0.85/Share beating the analyst estimate of $0.83/Share by a difference of $0.02. Therefore 41% are positive. GlaxoSmithKline PLC had 416 analyst reports since July 28, 2015 according to SRatingsIntel. As per Thursday, July 14, the company rating was upgraded by Jefferies. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of GlaxoSmithKline in a research note on Thursday.

GlaxoSmithKline plc (NYSE:GSK) closed its last session at $36.4. GlaxoSmithKline plc has a one year low of $34.52 and a one year high of $44.53. The rating was upgraded by Bank of America to "Neutral" on Tuesday, September 8. Zacks Investment Research lowered shares of GlaxoSmithKline from a "buy" rating to a "hold" rating in a research note on Wednesday. The stock of GlaxoSmithKline plc (NYSE:GSK) has "Buy" rating given on Thursday, October 20 by Investec.

Other reports by Click Lancashire

Discuss This Article